FDA told CYDY to stop eINDs and focus on completin
Post# of 148288
NP tried to spin it favorably, but my read of the situation is more spot on.
That the FDA said they would not allow any more eINDs is an indication that they acknowledge that leronlimab is legitimate based on the "anecdotal" results from the large sample size of eINDs. In other words, they DO NOT want to give leronlimab any more ammo.
FDA wants to remain in control and to control the narrative. The less sample size leronlimab has, anecdotal or otherwise, the better for their/BP agenda. Trials take time. Evidence is immediate.